TREO腹主动脉覆膜支架腔内修复术的五年结局
该研究分析了2016至2017年间连续37例接受TREO腹主动脉覆膜支架腔内修复术(EVAR)患者的术后随访,其中27例至少符合一项解剖困难标准、11例超出器械说明书使用。平均随访66个月(5.5年)期间,总体再干预率为5.5%,动脉瘤囊平均缩小11.25±8.30 mm,作者认为TREO在困难与友好解剖条件下均能维持中长期良好结果。
要点
- 37例中27例至少符合一项解剖困难标准,11例超出器械说明书使用范围。
- 平均随访66个月(5.5年),总体再干预率5.5%,动脉瘤囊平均缩小11.25±8.30 mm。
- 围手术期技术成功率100%,无围手术期死亡,总生存率91.9%。
核心结论
- 作者认为TREO腹主动脉覆膜支架在困难和友好主动脉解剖条件下,中长期并发症率和再干预率均维持了当前文献(ITA-ENDOBOOT注册研究)所报告的中期良好结果,动脉瘤囊缩小率令人满意。
研究设计与样本
- 对2016至2017年间连续37例接受TREO腹主动脉覆膜支架EVAR患者的术后随访进行分析,其基线临床情况、手术数据和短期结局已于2018年发表。
- 所有患者在术后6个月、12个月和5年接受CT血管造影(CTA)随访。
- 主要终点为主动脉相关死亡、I-III型内漏和再干预率;次要终点为II型内漏率和动脉瘤囊回缩。
主要发现
- 37例中27例至少符合一项解剖困难标准,11例在器械特异性说明书使用范围外完成手术。
- 围手术期技术成功率为100%,无围手术期死亡。
- 平均随访5.5年(66个月)期间,3例(8.1%)失访,3例(8.1%)死于非主动脉原因,总生存率为91.9%。
- 观察到1例困难瘤颈(但在说明书使用范围内)AAA的IA型内漏和1例标准解剖AAA的III型内漏,均通过腔内再衬附治疗,总体再干预率为5.5%。
- 4例II型内漏与动脉瘤囊随时间稳定相关,仍在监测中;动脉瘤囊平均缩小11.25±8.30 mm。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Newer generation abdominal endografts, including Treo (Terumo Aortic, Sunrise, Florida), have shown optimal safety and effectiveness in treating abdominal aortic aneurysms (AAAs), even with hostile anatomy over the short- and mid-term. The durability of such results, however, is still a controversial issue, due to the paucity of long-term data. Our aim is to show the long-term outcomes of endovascular aortic repair of both standard and hostile AAAs with the Treo endograft on a cohort of patients treated between 2016 and 2017. METHODS: We analyzed the postoperative follow-up of 37 consecutive patients who have undergone endovascular aortic repair (EVAR) with the Treo Endograft between 2016 and 2017, whose baseline clinical conditions, operative data, and short-term outcomes had been published in 2018. All patients were followed up by computed tomography angiography (CTA) at 6 and 12 months and 5 years postoperatively. Primary endpoints were aortic-related mortality, type I-III endoleak (EL), and reintervention rate. Secondary endpoints were the rates of type II ELs and aneurysm sac regression. RESULTS: Of 37 patients, 27 had at least one criterion of anatomic hostility and 11 were performed outside the device-specific instructions for use (IFU). In the perioperative period, we observed 100% technical success, with no perioperative mortality. Over a mean follow-up of 5.5 years (66 months), 3 patients (8.1%) were lost to follow-up and 3 (8.1%) died of non-aortic causes (overall survival: 91.9%). One type IA EL of an AAA with a hostile neck (but within the IFU) and a type III EL of an AAA with standard anatomy were observed and treated by endovascular relining (overall reintervention rate: 5.5%). Four type II ELs were associated with aneurysm sac stability over time and are still under surveillance. Mean aneurysm shrinkage was 11.25±8.30 mm. CONCLUSION: The optimal results of the Treo Endograft in terms of complication and reintervention rates reported over the mid-term by the current literature (ITA-ENDOBOOT registry) are maintained on the long term, both in case of hostile and friendly aortic anatomy, with a satisfactory shrinkage rate of the aneurysm sac. CLINICAL IMPACT: The innovative characteristics of Treo and its short-term results are well-known and reported. The present case series contributes to the scientific validation of a new-generation abdominal aortic endograft over the long-term, focusing especially on its performance in treating AAAs with hostile anatomy. Its 5-years outcomes confirm the optimal results already reported over the short- and mid-term.
引用
- Marone EM, Marazzi G, Brioschi C, et al. Five-Year Outcomes of Endovascular Aortic Repair With the TREO Abdominal Endograft. J Endovasc Ther. 2023. PMID: 37118936. doi:10.1177/15266028231170161
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。